{"id":1387,"date":"2026-05-06T14:02:00","date_gmt":"2026-05-06T12:02:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=94421be0d9a773eb61d43379e735264f"},"modified":"2026-05-06T14:02:00","modified_gmt":"2026-05-06T12:02:00","slug":"fujifilm-biosciences-and-nextcell-launch-new-commercial-platform-comprised-of-ruo-stromal-cells-and-cell-culture-media","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=1387","title":{"rendered":"FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<i>Collaboration results in platform to help researchers overcome challenges in MSC research<\/i><\/li>\n<li>\n<i>NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product or bundled with PRIME-XV media from FUJIFILM Biosciences<\/i><\/li>\n<\/ul><p>SANTA ANA, Calif. & HUDDINGE, Sweden--(BUSINESS WIRE)--FUJIFILM Biosciences, a global leader in the life science market, and NextCell Pharma AB, a clinical-stage company specializing in cell therapy using umbilical cord mesenchymal stromal cells (MSC), today announced a global commercial launch resulting from their strategic collaboration. The offering consists of FUJIFILM Biosciences\u2019 PRIME-XV MSC Expansion XSFM medium and NextCell\u2019s first commercial product, NextCell-Cord RUO, a research-use-only (RUO) MSC product derived from umbilical cord tissue.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260506274310\/en\/2796688\/5\/FUJIFILM_twitter_size.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260506274310\/en\/2796688\/22\/FUJIFILM_twitter_size.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260506274310\/en\/2796688\/5\/FUJIFILM_twitter_size.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260506274310\/en\/2796688\/21\/FUJIFILM_twitter_size.jpg\" \/><\/a><p>\nSome of the challenges faced in MSC research are heterogeneity of MSCs, immunocompatibility, and inefficient manufacturing. NextCell-Cord RUO provides researchers a more consistent, efficient, and accessible source of cells. The collaboration with FUJIFILM Biosciences to provide these cells with media delivers a high-quality, standardized solution for researchers working in immunology, regenerative medicine, and cell therapy development.<\/p><p>\nNextCell-Cord RUO is available across all major global markets through FUJIFILM Biosciences as a standalone product or bundled with Fujifilm\u2019s PRIME-XV MSC Expansion XSFM media, recombinant growth factors and reagents.<\/p><p>\n\u201c<i>FUJIFILM Biosciences is committed to paving a better way forward with life science products, services, and solutions that serve the evolving needs of our academia, biotech, and pharmaceutical partners worldwide,<\/i>\u201d <b>said Brandon Pence, president and chief operations officer at FUJIFILM Biosciences.<\/b> \u201c<i>Our strategic alliance with NextCell Pharma further strengthens our commitment to enabling our customers to achieve more with products and solutions they need every day to help create a healthier world for all.<\/i>\u201d<\/p><p>\n\u201c<i>This product launch is a milestone for NextCell Pharma AB,<\/i>\u201d<i> <\/i><b>said Mathias Svahn, chief executive officer of NextCell Pharma AB.<\/b> \u201c<i>It brings our proprietary MSC platform to a global audience, and we are proud to do so in close collaboration with FUJIFILM Biosciences, a trusted leader in life science solutions.<\/i>\u201d<\/p><p>\n\u201c<i>We\u2019ve worked with FUJIFILM Biosciences to ensure that this product meets the needs of researchers and drug developers who value consistency, scalability, and translational relevance,<\/i>\u201d <b>said Dr. Lindsay Davies, chief scientific officer at NextCell Pharma AB. <\/b>\u201c<i>NextCell-Cord RUO reflects not only our clinical manufacturing expertise, but also a commitment to delivering high-quality, standardized MSC products that are scientifically robust and immediately usable in research and development workflows.<\/i>\u201d<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Media Contacts:<\/b><\/p><p>\nLori Serles\n<br\/>FUJIFILM Biosciences\n<br\/>Phone: (949) 261-7800\n<br\/>Email: <a  href=\"mailto:lori.serles@fujifilm.com\" rel=\"nofollow\" shape=\"rect\">lori.serles@fujifilm.com<\/a><\/p><p>\nLily Jeffery\n<br\/>Zyme Communications\n<br\/>Phone: +44 (0)7891 477 378\n<br\/>Email: <a  href=\"mailto:lily.jeffery@zymecommunications.com\" rel=\"nofollow\" shape=\"rect\">lily.jeffery@zymecommunications.com<\/a><\/p><p>\nMathias Svahn, CEO\n<br\/>NextCell Pharma AB\n<br\/>Tel: +46 8 735 5595\n<br\/>E-mail: <a  href=\"mailto:info@nextcellpharma.com\" rel=\"nofollow\" shape=\"rect\">info@nextcellpharma.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Collaboration results in platform to help researchers overcome challenges in MSC research<\/p>\n<p>NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product or bundled with PRIME-XV media from FUJIFILM Biosciences<br \/>\nSANTA&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1387","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/1387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1387"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/1387\/revisions"}],"predecessor-version":[{"id":1388,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/1387\/revisions\/1388"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}